Management of Hematologic Disorders

  • Author: David Aboulafia, MD (More Info)
  • Editors in Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
  • Last Reviewed: 4/1/16 (What's New)

Summary

  • Anti-Rh antibody [drug: RHo D immune globulin] requires use of lower amounts of antibody than gamma globulin and is less costly, but there is risk of RBC hemolysis[Oksenhendler 1988; FDA Rho (D) Immune Globulin]
  • [drug: RHo D immune globulin] produces ~ 64% short-term response rate and more sustained platelet response than gamma globulin[Oksenhendler 1988]

Action required

Keywords: Hematologic Complications

©2020 Clinical Care Options, LLC. All Rights Reserved.

The materials published via inPractice® reflect the views of the reviewers or authors of the material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.